Holen Sie sich die Stockscreener-App
10.63
2.12%
-0.23
Handel nachbörslich:
10.63
Schlusskurs vom Vortag:
$10.86
Offen:
$10.82
24-Stunden-Volumen:
370.47K
Relative Volume:
0.28
Marktkapitalisierung:
$701.26M
Einnahmen:
$2.81M
Nettoeinkommen (Verlust:
$-97.34M
KGV:
-6.7278
EPS:
-1.58
Netto-Cashflow:
$-91.47M
1W Leistung:
+9.14%
1M Leistung:
+3.71%
6M Leistung:
+55.18%
1J Leistung:
+186.52%
1-Tages-Spanne:
$10.62
$11.17
1-Wochen-Bereich:
$9.37
$11.17
52-Wochen-Spanne:
$2.315
$15.74
Fulcrum Therapeutics Inc Stock (FULC) Company Profile
Firmenname
Fulcrum Therapeutics Inc
Sektor
Branche
Telefon
617-651-8851
Adresse
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Compare FULC vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
FULC
Fulcrum Therapeutics Inc
|
10.63 | 716.44M | 2.81M | -97.34M | -91.47M | -1.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 12.04B | 3.95B | 3.34B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Fulcrum Therapeutics Inc Stock (FULC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-12 | Eingeleitet | JP Morgan | Overweight |
| 2025-11-24 | Eingeleitet | Truist | Buy |
| 2025-07-29 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-05-23 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-05-15 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2024-09-13 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-09-12 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2024-09-12 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2024-09-12 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-09-12 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-09-12 | Herabstufung | Stifel | Buy → Hold |
| 2024-09-09 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2024-05-20 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-03-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-09-25 | Eingeleitet | Goldman | Neutral |
| 2023-08-23 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2023-08-22 | Hochstufung | Stifel | Hold → Buy |
| 2023-05-04 | Herabstufung | Goldman | Buy → Neutral |
| 2023-03-10 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2023-03-10 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-03-09 | Herabstufung | Stifel | Buy → Hold |
| 2023-02-28 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-02-24 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-11-15 | Eingeleitet | Goldman | Buy |
| 2022-03-08 | Eingeleitet | Oppenheimer | Outperform |
| 2022-03-03 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2021-08-11 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-03-22 | Eingeleitet | Credit Suisse | Outperform |
| 2021-03-02 | Eingeleitet | Stifel | Buy |
| 2020-10-16 | Eingeleitet | Piper Sandler | Overweight |
| 2020-08-12 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-08-12 | Bestätigt | H.C. Wainwright | Buy |
| 2020-08-12 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-06-19 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2020-06-17 | Eingeleitet | BTIG Research | Buy |
| 2019-10-03 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-08-12 | Eingeleitet | BofA/Merrill | Buy |
Alle ansehen
Fulcrum Therapeutics Inc Aktie (FULC) Neueste Nachrichten
Can Fulcrum Therapeutics Inc. stock deliver surprise earnings beatCPI Data & Verified Entry Point Detection - mfd.ru
Will Fulcrum Therapeutics Inc. stock benefit from infrastructure spendingJuly 2025 Gainers & Reliable Entry Point Trade Alerts - mfd.ru
Why Fulcrum Therapeutics Inc. stock attracts high net worth investors2025 Market Overview & Safe Entry Momentum Tips - mfd.ru
Will Fulcrum Therapeutics Inc. stock benefit from automation2025 Winners & Losers & Low Risk High Win Rate Picks - mfd.ru
Facioscapulohumeral Muscular Dystrophy Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Dyne Therapeutics, miRecule, Avidity Biosciences, aTyr Pharma, Fulcrum Therapeutics - Barchart.com
Facioscapulohumeral Muscular Dystrophy Market: High-Growth - openPR.com
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Wall Street Analysts See a 75.71% Upside in Fulcrum Therapeutics (FULC): Can the Stock Really Move This High? - Finviz
Fulcrum Therapeutics (NASDAQ:FULC) Trading Up 1.1%What's Next? - MarketBeat
Facioscapulohumeral Muscular Dystrophy Pipeline 2025: Key - openPR.com
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Decliners Report: Can Fulcrum Therapeutics Inc maintain sales growthJuly 2025 PreEarnings & High Return Stock Watch Alerts - baoquankhu1.vn
Insider Sell: Robert Gould Sells 15,000 Shares of Fulcrum Therap - GuruFocus
Sectors Review: Is Fulcrum Therapeutics Inc stock undervalued right nowWeekly Profit Summary & Long-Term Capital Growth Ideas - baoquankhu1.vn
Pharma News: Can Fulcrum Therapeutics Inc maintain sales growthIndex Update & Weekly High Conviction Trade Ideas - baoquankhu1.vn
Can Fulcrum Therapeutics Inc disrupt its industry2025 Support & Resistance & Precise Swing Trade Alerts - baoquankhu1.vn
Can Fulcrum Therapeutics Inc keep up with sector leadersJuly 2025 Recap & Daily Profit Maximizing Trade Tips - baoquankhu1.vn
Will Fulcrum Therapeutics Inc. stock sustain high P E ratiosJuly 2025 Momentum & Consistent Return Investment Signals - mfd.ru
Fulcrum Therapeutics, Inc. (FULC) Stock Analysis: Exploring an 82% Potential Upside Amid Clinical Innovations - DirectorsTalk Interviews
Facioscapulohumeral Muscular Dystrophy Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Fulcrum Therapeutics, Dyne Therapeutics, GSK, Roche, Facio Therapies - Barchart.com
Published on: 2026-01-29 20:30:44 - baoquankhu1.vn
Aug Setups: Will ESNT outperform tech stocksPortfolio Profit Report & Intraday High Probability Alerts - baoquankhu1.vn
Rally Mode: Can Fulcrum Therapeutics Inc. keep up with sector leaders2025 Growth vs Value & AI Driven Stock Reports - baoquankhu1.vn
Trend Report: What is the target price for ALKS stock2025 Year in Review & Fast Gaining Stock Reports - baoquankhu1.vn
Is Fulcrum Therapeutics Inc benefiting from innovation trendsCPI Data & Weekly Top Gainers Trade List - baoquankhu1.vn
Big Money Moves: Can Fulcrum Therapeutics Inc deliver alphaProduct Launch & Safe Entry Momentum Tips - baoquankhu1.vn
Fulcrum Therapeutics, Inc. (FULC) Stock Analysis: Potential Upside Amidst Biotech Innovations - DirectorsTalk Interviews
Analyst Calls: Will Fulcrum Therapeutics Inc benefit from seasonality2025 Stock Rankings & Real-Time Volume Analysis Alerts - baoquankhu1.vn
Downgrade Watch: Can Fulcrum Therapeutics Inc disrupt its industryQuarterly Portfolio Review & Smart Money Movement Alerts - baoquankhu1.vn
Campbell & CO Investment Adviser LLC Takes Position in Fulcrum Therapeutics, Inc. $FULC - MarketBeat
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
IPO Launch: Can Fulcrum Therapeutics Inc deliver alpha2025 Earnings Surprises & AI Powered Trade Plan Recommendations - baoquankhu1.vn
Insider Sell: Is Canadian Imperial Bank of Commerces growth already priced in2025 Stock Rankings & AI Forecasted Entry and Exit Points - baoquankhu1.vn
Fulcrum Therapeutics (FULC) Receives a Sell from Bank of America Securities - The Globe and Mail
Fulcrum Therapeutics (NASDAQ:FULC) Cut to Sell at Wall Street Zen - MarketBeat
Block Trades: Is Fulcrum Therapeutics Inc part of any ETF2025 Fundamental Recap & Real-Time Volume Triggers - baoquankhu1.vn
Can Fulcrum Therapeutics Inc. disrupt its industryWeekly Trading Summary & Free Low Drawdown Momentum Trade Ideas - bollywoodhelpline.com
Fulcrum Therapeutics (NASDAQ:FULC) Shares Up 7.8%What's Next? - MarketBeat
Whale Trades: Is Fulcrum Therapeutics Inc stock dividend yield sustainable2025 Investor Takeaways & Daily Profit Maximizing Tips - Bộ Nội Vụ
Gains Recap: Whats the fair value of Fulcrum Therapeutics Inc stock2025 Valuation Update & Safe Capital Growth Plans - baoquankhu1.vn
Fulcrum Therapeutics (NASDAQ:FULC) Coverage Initiated by Analysts at JPMorgan Chase & Co. - Defense World
JP Morgan Initiates Coverage of Fulcrum Therapeutics (FULC) with Overweight Recommendation - Nasdaq
Fulcrum Therapeutics (NASDAQ:FULC) Shares Gap UpShould You Buy? - MarketBeat
This Netflix Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
JPMorgan Initiates Coverage on Fulcrum Therapeutics With Overweight Rating, $20 Price Target - marketscreener.com
Wall Street analysts think Fulcrum Therapeutics (FULC) could surge 58.47%: Read this before placing a bet - MSN
Fulcrum Therapeutics announces proposed $150.0 million public offering of common stock - MSN
Can Fulcrum Therapeutics Inc. stock beat market expectations this quarterFootwear buying guidance for consistent weekly training mileage focuses on stable support and balance, making it a solid option for daily use. - ulpravda.ru
How Fulcrum Therapeutics Inc. stock performs in stagflation2025 Market Sentiment & Verified Entry Point Signals - Улправда
Star TribuneFulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - FinancialContent
Can Fulcrum Therapeutics Inc. stock surprise with earnings upside2025 Volume Leaders & Stock Timing and Entry Methods - Улправда
Finanzdaten der Fulcrum Therapeutics Inc-Aktie (FULC)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.12%
0.87%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):